These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27486994)

  • 1. Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma.
    Boons CC; Wagner C; Hugtenburg JG
    Oncol Res Treat; 2016; 39(7-8):417-22. PubMed ID: 27486994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China.
    Li J; Wang S; Wang Y; Wang X; Wang H; Feng J; Zhang Q; Sun T; Ouyang Q; Yin Y; Liu Y; Geng C; Yan M; Jiang Z
    Oncologist; 2017 Nov; 22(11):1333-1338. PubMed ID: 28798274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly.
    van Rooijen JM; de Munck L; Teeuwen GM; de Graaf JC; Jansman FG; Boers JE; Siesling S
    Anticancer Drugs; 2016 Feb; 27(2):127-32. PubMed ID: 26473525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab treatment of patients with early, HER2-positive breast cancer in 17 certified German breast cancer centers.
    Sibert NT; Wesselmann S; Breidenbach C; Blohmer J; Brückner B; Gebauer G; Dos Santos Guilherme M; Hartkopf A; Lindner C; Peschel S; Rieger L; Schad F; Strecker P; Ferencz J; Dieng S; Inwald EC; Kowalski C; Ortmann O
    J Cancer Res Clin Oncol; 2022 Mar; 148(3):719-726. PubMed ID: 33914125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.
    Dvortsin E; Gout-Zwart J; Eijssen EL; van Brussel J; Postma MJ
    PLoS One; 2016; 11(1):e0146551. PubMed ID: 26800029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients.
    Phillips KA; Marshall DA; Haas JS; Elkin EB; Liang SY; Hassett MJ; Ferrusi I; Brock JE; Van Bebber SL
    Cancer; 2009 Nov; 115(22):5166-74. PubMed ID: 19753618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic breast cancer: a large observational study on adherence to French prescribing guidelines and financial cost of the anti-HER2 antibody trastuzumab.
    Poncet B; Colin C; Bachelot T; Jaisson-Hot I; Derain L; Magaud L; Fournel-Federico C; Mousseau M; Tigaud JD; Jacquin JP; Trillet-Lenoir V
    Am J Clin Oncol; 2009 Aug; 32(4):369-74. PubMed ID: 19381078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of trastuzumab in metastatic breast cancer: mainly a matter of price in the EU?
    Garattini L; van de Vooren K; Curto A
    Health Policy; 2015 Feb; 119(2):212-6. PubMed ID: 25523144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.
    Colomer R; Hall P; Szkultecka-Debek M; Bondi RC; Flinois A; Auziere S; Le Cléac'h JY
    Breast Cancer Res Treat; 2018 Feb; 168(1):197-205. PubMed ID: 29170976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost considerations in determining the affordability of adjuvant trastuzumab in breast cancer.
    Abratt RP
    S Afr Med J; 2016 Sep; 106(10):981-982. PubMed ID: 27725014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden.
    Wilking U; Jönsson B; Wilking N; Bergh J
    Acta Oncol; 2010 Aug; 49(6):844-50. PubMed ID: 20615172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice.
    Visser A; van de Ven EM; Ruczynski LI; Blaisse RJ; van Halteren HK; Aben K; van Laarhoven HW
    Acta Oncol; 2016; 55(4):423-9. PubMed ID: 26217988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?
    Franken MG; Gaultney JG; Blommestein HM; Huijgens PC; Sonneveld P; Redekop WK; Uyl-de Groot CA
    Value Health; 2014 Mar; 17(2):245-53. PubMed ID: 24636383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Guideline Adherence in Colorectal Cancer Treatment in The Netherlands: A Survey Among Medical Oncologists by the Dutch Colorectal Cancer Group.
    Keikes L; van Oijen MGH; Lemmens VEPP; Koopman M; Punt CJA
    Clin Colorectal Cancer; 2018 Mar; 17(1):58-64. PubMed ID: 29157662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.
    de Munck L; Schaapveld M; Siesling S; Wesseling J; Voogd AC; Tjan-Heijnen VC; Otter R; Willemse PH
    Breast Cancer Res Treat; 2011 Aug; 129(1):229-33. PubMed ID: 21431871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
    Garrison LP; Veenstra DL
    Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment.
    Barron JJ; Cziraky MJ; Weisman T; Hicks DG
    Oncologist; 2009 Aug; 14(8):760-8. PubMed ID: 19684074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement.
    Gaultney JG; Franken MG; Uyl-de Groot CA; Redekop WK; Huijgens PC; van der Holt B; Lokhorst HM; Sonneveld P
    Health Policy; 2015 Feb; 119(2):186-94. PubMed ID: 25476554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.